Yerke Suleimenova

Dr. Yerke Suleimenova

Clinical Pharmacology, NpJSC "Astana Medical University", Nur-Sultan, Astana, Kazakhstan
orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
Yerke SuleimenovaYerke Suleimenova
Yerke Suleimenova
Indira KaribayevaIndira Karibayeva
Indira Karibayeva
Шнара СветлановаШнара Светланова
Шнара Светланова
Nurzhamal AkhmadyarNurzhamal Akhmadyar
Nurzhamal Akhmadyar
DBDinagul Bayesheva
Dinagul Bayesheva
ABAida Bolatbek
Aida Bolatbek
Background/Objectives: Rotavirus remains a major cause of acute gastroenteritis among children under five years of age, particularly in regions with heterogeneous vaccine implementation. In Central Asia, differences in the timing and coverage of rotavirus vaccination may influence circulating genotype patterns, yet regional evidence remains fragmented. Methods: A systematic review and meta-analysis were conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD420251274198). Electronic databases (PubMed, Web of Science, ScienceDirect, and Google Scholar) were searched without date restrictions. Studies reporting laboratory-confirmed rotavirus infection and genotype distribution among children under five years in Central Asia were included. Random-effects meta-analysis of proportions was performed to estimate the pooled genotype proportions among rotavirus-positive children, with subgroup analyses comparing the before and after vaccine introduction periods. Results: Six studies (ten before vaccine introduction strata and four after vaccine introduction strata; N = 1713 rotavirus-positive children) were included. A significant decline in the G1P[8] genotype was observed following vaccine introduction, with pooled prevalence decreasing from 0.468 (95% CI: 0.363–0.577) to 0.068 (95% CI: 0.034–0.133) (p < 0.001). In contrast, G2P[4] increased from 0.134 to 0.485 (p < 0.001), while G9P[4] and G9P[8] also increased significantly. G3P[8] and mixed genotypes declined, whereas G4P[8], G12P[8], and untypable strains showed no statistically significant subgroup differences. Substantial heterogeneity was observed (I2 > 90%), and evidence certainty was very low for all genotype outcomes. Conclusions: The available evidence suggests that rotavirus genotype distribution among children under five in Central Asia may have changed after vaccine introduction, with lower pooled proportions of G1P[8] and higher proportions of selected heterotypic genotypes in after vaccine introduction strata. Strengthened molecular surveillance using standardized genotyping protocols is needed to determine whether these patterns represent sustained genotype replacement or temporal fluctuation. These estimates are based on a small, heterogeneous evidence base with very low certainty and should be considered hypothesis-generating rather than confirmatory of a causal vaccine effect.

13 October 2026 in Central Asian Journal of Nephrology
Verified
Journal Article
Open access
PDF file
Yerke SuleimenovaYerke Suleimenova
Yerke Suleimenova
SMSaltanat Moldakhmetova
Saltanat Moldakhmetova
AKAbuali Kuspanov
Abuali Kuspanov
AAAinur Abdrakhmanova
Ainur Abdrakhmanova
ZAZikrillo Artikov
Zikrillo Artikov
AGAbduzhappar Gaipov
Abduzhappar Gaipov
Background: Chronic kidney disease (CKD) is very important to have biomarker that can be detected in time before kidney function is impaired, because it is only detected at very late stages. CD44 is a potential biomarker for kidney injury, involved in inflammation and fibrosis. Methods: This cross-sectional study included 137 participants: The concentration of CD44 urine was measured by enzyme-linked immunosorbent assay (ELISA), and proteomic analysis was performed by mass spectrometry. For assessment, estimated glomerular filtration rate (eGFR) and 24-hour proteinuria have been monitored, while accounting for clinical and laboratory parameters. The correlation between kidney function and CD44 levels was determined using Spearman’s rank correlation. Results: The level of CD44 in urine, as detected by ELISA, was higher in healthy controls than in CKD patients (p = 0.007). In addition, a positive correlation was observed between CD44 levels and eGFR (Spearman’s rho = 0.2808, p = 0.0052), indicating that higher CD44 levels are associated with kidney function. Proteomic analysis confirmed these results, showing a significant relationship between CD44 expression and kidney function parameters. Conclusion: The research results demonstrate that CD44 levels in urine differ significantly between healthy individuals and CKD patients, suggesting that CD44 may be a candidate biomarker associated with kidney function. Further investigation in large-scale studies is required to confirm its clinical applicability.